Biomedical Engineering Reference
In-Depth Information
4.1.5
Whole-Body
Stoeckli et al. [
155
] reported the whole-body imaging by MALDI. Three HLA-B27
transgenic mice were dosed intravenously with 0.5 mL of a saline solution of
b-peptide at 2 mg/mL. A fourth mouse was dosed with 0.5 mL of a saline solution
of the Rheuma a-peptide at 2 mg/mL as a control. Mice treated with b -peptide were
sacrificed at 5 min, 1 h, and 24 h postdose (one mouse per time point). Matrix coat-
ing was obtained by spraying 4 mL per plate of a solution of 10 mg/mL CHCA in
acetonitrile-water (50:50) using a TLC sprayer.
MS imaging was carried out on whole-body sections of mice. No a -peptide
control was detected at 1 h postdose, while retention of the b-peptide was observed
for longer than 24 h postdose.
4.1.6
Cancer Tissue
Reyzer et al. [
156
] reported a study of the distribution of antitumor drug, SCH226374,
in mouse tumor tissue. The matrix SA was prepared at a 20 mg/mL in ACN/0.2%TFA
(50:50). The matrix solution was applied onto the tissues using the spotting and
spray. The MALDI images were created using the selected reaction monitoring
(SRM) technique to monitor the transition of [M+H]
+
m/z
695 >
m/z
228. The MS
image indicated that the drug was present over most of the tumor but was concen-
trated in the outer periphery.
4.1.7
Retina
Hayasaka et al. [
157
] reported the determination of the fatty acid distribution in
mouse retina by using AgNPs in nano-PALDI-IMS. The sections were sliced to a
thickness of 10 mm and sprayed with AgNPs or DHB matrix solution at 50 mg/mL
in 70 % methanol/0.1%TFA. The mouse retinal sections were analyzed at a high
spatial resolution with a scan pitch of 10 mm. The MS images showed the distribu-
tion of palmitic acid, linoleic acid, oleic acid, stearic acid, eicosapentaenoic acid
(EPA), arachidonic acid, and docosahexaenoic acid (DHA).
4.2
Application to Human Cancer Tissue
Atkinson [
158
] reported a study on the distribution of banoxatrone (AQ4N) in
human cancer tissue by MALDI MS. In hypoxic cells AQ4N is reduced to the
topoisomerase II inhibitor AQ4. CHCA at 25 mg/mL in ethanol with 1.0 % TFA
was used as matrix. The distribution of AQ4N and AQ4 in treated H460 human
tumor xenografts was examined by MALDI MS imaging in positive ion acquisi-
tion mode. Images of the distribution of AQ4N and AQ4 showed little overlap.
